{"id":730195,"date":"2021-03-10T21:01:00","date_gmt":"2021-03-10T21:01:00","guid":{"rendered":"https:\/\/www.pm360online.com\/?guid=fd9aa8fad28b937fa616a95aadb119cd"},"modified":"2021-03-10T21:01:00","modified_gmt":"2021-03-10T21:01:00","slug":"ascendis-pharma-a-s-reports-full-year-2020-financial-results-2","status":"publish","type":"post","link":"https:\/\/www.pm360online.com\/ascendis-pharma-a-s-reports-full-year-2020-financial-results-2\/","title":{"rendered":"Ascendis Pharma A\/S Reports Full Year 2020 Financial Results"},"content":{"rendered":"<p><![CDATA[\u2013 Preparations for potential launch of first Endocrinology Rare Disease product candidate, TransCon hGH (lonapegsomatropin), continues on track \u2013]]><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":74553,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[71350,71355],"tags":[],"_links":{"self":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/730195"}],"collection":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/users\/74553"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/comments?post=730195"}],"version-history":[{"count":0,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/730195\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/media?parent=730195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/categories?post=730195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/tags?post=730195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}